Spots Global Cancer Trial Database for Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
Official Title: A Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer
Study ID: NCT00494338
Conditions
Interventions
Study Description
Brief Summary: A multi-center controlled, non-comparative open Phase II trial of docetaxel and celecoxib in patients with metastatic androgen independent prostate cancer where efficacy is measured by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Sanofi-Aventis, Sao Paulo, , Brazil
Contact Details
Name: Jaderson Lima, M.D.
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
